Cell therapy in dilated cardiomyopathy: from animal models to clinical trials

• Main Authors: C. del Corsso, A.C. Campos de Carvalho
• Format: Article
• Language: English
• Published: Associação Brasileira de Divulgação Científica 2011-05-01
• Series: Brazilian Journal of Medical and Biological Research
• Subjects: Dilated cardiomyopathy; Stem cell; Heart failure; Chagas’ disease; Cell therapy
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011000500002
• ISSN: 0100-879X; 1414-431X

Dilated cardiomyopathy can be the end-stage form and common denominator of several cardiac disorders of known cause, such as hypertensive, ischemic, diabetic and Chagasic diseases. However, some individuals have clinical findings, such as an increase in ventricular chamber size and impaired contractility (classical manifestations of dilated cardiomyopathy) even in the absence of a diagnosed primary disease. In these patients, dilated cardiomyopathy is classified as idiopathic since its etiology is obscure. Nevertheless, regardless of all of the advances in medical, pharmacological and surgical procedures, the fate of patients with dilated cardiomyopathy (of idiopathic or of any other known cause) is linked to arrhythmic episodes, severe congestive heart failure and an increased risk of sudden cardiac death. In this review, we will summarize present data on the use of cell therapies in animal models of dilated cardiomyopathies and will discuss the few clinical trials that have been published so far involving patients affected by this disease. The animal models discussed here include those in which the cardiomyopathy is produced by genetic manipulation and those in which disease is induced by chemical or infectious agents. The specific model used clearly creates restrictions to translation of the proposed cell therapy to clinical practice, insofar as most of the clinical trials performed to date with cell therapy have used autologous cells. Thus, translation of genetic models of dilated cardiomyopathy may have to wait until the use of allogeneic cells becomes more widespread in clinical trials of cell therapies for cardiac diseases.